Comparison Overview

Eurolife Healthcare Pvt Ltd

VS

Ipca Laboratories Limited

Eurolife Healthcare Pvt Ltd

901 B, Tower 2, Indiabulls Finance Center Mumbai, Maharashtra 400013, IN
Last Update: 2025-03-14 (UTC)

We are the No. 1 company in the Intravenous Infusion business in India. Eurolife Healthcare Pvt. Ltd. is a Mumbai based Pharmaceutical company, incorporated in the year 2001. We manufacture and distribute an exclusive portfolio of healthcare formulations, Intravenous Infusions, Ophthalmics, Sterilized water for Injections, Nebules, Tablets, Capsules, Ointment and Creams(Topicals). We provide benchmark quality – Large Volume Parenterals / Small Volume Parenterals for the consumers at most economical prices. Eurolife is recognised for its High Standard of Quality that it maintains and the approvals which it has for all it's plant. The plants are WHO - GMP and ISO certified. While maintaining these Quality Standards, 2017 has been marked as a prominent year for us. We acquired FFS unit of Baxter along with its two manufacturing units in Waluj and Alathur. A glance of our maintenance of high Quantity Standards; we have passed Ukraine Audit, now becoming a PIC'S approved organisation. Eurolife has the largest Distribution network in South East Asia. We have Sales and Marketing footprints across major emerging markets. Have four manufacturing plants disseminated in different geographies with two factory units in Roorkee being in the North, Waluj in West and Alathur in South. We have unparalleled reach across India and fastest turnaround time to market response. We have a strong base in Exports as well, we export to appox. 25 countries worldwide. Eurolife is Recognized Star Export House by Government of India.

NAICS: 325
NAICS Definition:
Employees: 501-1,000
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0

Ipca Laboratories Limited

125 Kandivli Industrial Estate Kandivli (West) Mumbai, Maharashtra 400067, IN
Last Update: 2025-05-17 (UTC)
Between 750 and 799

A consumer-led global pharmaceutical company, creating healthy doses of life since 1949. When you operate in an industry like pharmaceuticals, your work goes way beyond creating ‘products for customers’. It is different from any other domain – there lies a higher sense of responsibiliti and a need for utmost integriti in everything you do. As you serve millions of lives, high qualiti standards become a pre-requisite, and safeti of your people and consumers always comes first. All this, while ensuring that each life you touch is treated with respect and digniti. For more than 60 years, Ipca has been a crucial healthcare partner in over 120 countries across the 6 continents. We are a fully-integrated pharmaceutical company that manufactures over 350 formulations and 80 APIs for various therapeutic segments. Today, we are one of the world’s largest manufacturers and suppliers of over a dozen APIs. These are produced from scratch at fully-automated manufacturing facilities, approved by the world’s most discerning drug regulatory authorities like UK-MHRA, EDQM-Europe, and WHO-Geneva, among others. - One of the largest suppliers of these APIs worldwide with manufacturing leadership in over 12 APIs globally - 15 APIs & 11 Formulations manufacturing facility across the globe Leader in DMARDs (Disease Modifying Anti-Rheumatic Drugs) treatment for Rheumatoid Arthritis - Leading brands in Pain, Rheumatology, Antimalarials and Hair care therapy - 4 formulations rank amongst the top 300 brands of IPM as per IQVIA

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 10,001+
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/eurolife-healthcare-pvt-ltd.jpeg
Eurolife Healthcare Pvt Ltd
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/ipca.jpeg
Ipca Laboratories Limited
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
Eurolife Healthcare Pvt Ltd
100%
Compliance Rate
0/4 Standards Verified
Ipca Laboratories Limited
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Eurolife Healthcare Pvt Ltd in 2025.

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Ipca Laboratories Limited in 2025.

Incident History — Eurolife Healthcare Pvt Ltd (X = Date, Y = Severity)

Eurolife Healthcare Pvt Ltd cyber incidents detection timeline including parent company and subsidiaries

Incident History — Ipca Laboratories Limited (X = Date, Y = Severity)

Ipca Laboratories Limited cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/eurolife-healthcare-pvt-ltd.jpeg
Eurolife Healthcare Pvt Ltd
Incidents

No Incident

https://images.rankiteo.com/companyimages/ipca.jpeg
Ipca Laboratories Limited
Incidents

No Incident

FAQ

Ipca Laboratories Limited company demonstrates a stronger AI Cybersecurity Score compared to Eurolife Healthcare Pvt Ltd company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

Historically, Ipca Laboratories Limited company has disclosed a higher number of cyber incidents compared to Eurolife Healthcare Pvt Ltd company.

In the current year, Ipca Laboratories Limited company and Eurolife Healthcare Pvt Ltd company have not reported any cyber incidents.

Neither Ipca Laboratories Limited company nor Eurolife Healthcare Pvt Ltd company has reported experiencing a ransomware attack publicly.

Neither Ipca Laboratories Limited company nor Eurolife Healthcare Pvt Ltd company has reported experiencing a data breach publicly.

Neither Ipca Laboratories Limited company nor Eurolife Healthcare Pvt Ltd company has reported experiencing targeted cyberattacks publicly.

Neither Eurolife Healthcare Pvt Ltd company nor Ipca Laboratories Limited company has reported experiencing or disclosing vulnerabilities publicly.

Neither Eurolife Healthcare Pvt Ltd nor Ipca Laboratories Limited holds any compliance certifications.

Neither company holds any compliance certifications.

Neither Eurolife Healthcare Pvt Ltd company nor Ipca Laboratories Limited company has publicly disclosed detailed information about the number of their subsidiaries.

Neither Eurolife Healthcare Pvt Ltd company nor Ipca Laboratories Limited company has publicly disclosed the exact number of their employees.

Neither Eurolife Healthcare Pvt Ltd nor Ipca Laboratories Limited holds SOC 2 Type 1 certification.

Neither Eurolife Healthcare Pvt Ltd nor Ipca Laboratories Limited holds SOC 2 Type 2 certification.

Neither Eurolife Healthcare Pvt Ltd nor Ipca Laboratories Limited holds ISO 27001 certification.

Neither Eurolife Healthcare Pvt Ltd nor Ipca Laboratories Limited holds PCI DSS certification.

Neither Eurolife Healthcare Pvt Ltd nor Ipca Laboratories Limited holds HIPAA certification.

Neither Eurolife Healthcare Pvt Ltd nor Ipca Laboratories Limited holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

The Bold Page Builder plugin for WordPress is vulnerable to Stored Cross-Site Scripting via the ‘percentage’ parameter in all versions up to, and including, 5.4.5 due to insufficient input sanitization and output escaping. This makes it possible for authenticated attackers, with Contributor-level access and above, to inject arbitrary web scripts in pages that will execute whenever a user accesses an injected page.

Risk Information
cvss3
Base: 6.4
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:C/C:L/I:L/A:N
Description

The ComboServlet in Liferay Portal 7.4.0 through 7.4.3.111, and older unsupported versions, and Liferay DXP 2023.Q4.0 through 2023.Q4.2, 2023.Q3.1 through 2023.Q3.5, 7.4 GA through update 92, 7.3 GA through update 35, and older unsupported versions does not limit the number or size of the files it will combine, which allows remote attackers to create very large responses that lead to a denial of service attack via the URL query string.

Risk Information
cvss4
Base: 6.9
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:N/VI:N/VA:L/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

A relative path traversal vulnerability was discovered in Productivity Suite software version 4.4.1.19. The vulnerability allows an unauthenticated remote attacker to interact with the ProductivityService PLC simulator and delete arbitrary directories on the target machine.

Risk Information
cvss3
Base: 4.0
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:C/C:N/I:L/A:N
cvss4
Base: 6.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:N/VI:L/VA:N/SC:N/SI:L/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

A relative path traversal vulnerability was discovered in Productivity Suite software version 4.4.1.19. The vulnerability allows an unauthenticated remote attacker to interact with the ProductivityService PLC simulator and create arbitrary directories on the target machine.

Risk Information
cvss3
Base: 4.0
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:C/C:N/I:L/A:N
cvss4
Base: 6.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:N/VI:L/VA:N/SC:N/SI:L/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

A relative path traversal vulnerability was discovered in Productivity Suite software version 4.4.1.19. The vulnerability allows an unauthenticated remote attacker to interact with the ProductivityService PLC simulator and delete arbitrary files on the target machine.

Risk Information
cvss3
Base: 7.5
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:C/C:N/I:L/A:H
cvss4
Base: 8.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:N/VI:L/VA:H/SC:N/SI:L/SA:L/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X